Mahdi Bagheri

InstitutionBaqiyatallah University of Medical Sciences
AddressTehran
Iran
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 6 Covid-19 publications, with a maximum of 2 publications in April 2020 and Spetember 2020
    All Publications
    Bar chart showing 10 publications over 5 distinct years, with a maximum of 5 publications in 2020
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Farnoosh G, Akbariqomi M, Badri T, Bagheri M, Izadi M, Saeedi-Boroujeni A, Rezaie E, Ghaleh HEG, Aghamollaei H, Fasihi-Ramandi M, Hassanpour K, Alishiri G. Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial. Arch Med Res. 2022 01; 53(1):79-85. PMID: 34229896.
      Citations: 6     Fields:    
    2. Hushmandi K, Bokaie S, Hashemi M, Moghadam ER, Raei M, Hashemi F, Bagheri M, Habtemariam S, Nabavi SM. A review of medications used to control and improve the signs and symptoms of COVID-19 patients. Eur J Pharmacol. 2020 Nov 15; 887:173568. PMID: 32956644.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    3. Nabavi SF, Habtemariam S, Sureda A, Banach M, Berindan-Neagoe I, Cismaru CA, Bagheri M, Bagheri MS, Nabavi SM. Glucose-6-phosphate dehydrogenase deficiency and SARS-CoV-2 mortality: Is there a link and what should we do? Clin Biochem. 2020 Dec; 86:31-33. PMID: 32950470.
      Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
    4. Sahebnasagh A, Saghafi F, Safdari M, Khataminia M, Sadremomtaz A, Talaei Z, Rezai Ghaleno H, Bagheri M, Habtemariam S, Avan R. Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19. J Clin Pharm Ther. 2020 Dec; 45(6):1515-1519. PMID: 32860252.
      Citations: 16     Fields:    Translation:Humans
    5. Nikpouraghdam M, Jalali Farahani A, Alishiri G, Heydari S, Ebrahimnia M, Samadinia H, Sepandi M, Jafari NJ, Izadi M, Qazvini A, Dorostkar R, Tat M, Shahriary A, Farnoosh G, Hosseini Zijoud SR, Taghdir M, Alimohamadi Y, Abbaszadeh S, Gouvarchin Ghaleh HE, Bagheri M. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. J Clin Virol. 2020 06; 127:104378. PMID: 32353762.
      Citations: 111     Fields:    Translation:HumansCellsPHPublic Health
    6. Nabavi SF, Habtemariam S, Clementi E, Berindan-Neagoe I, Cismaru CA, Rasekhian M, Banach M, Izadi M, Bagheri M, Bagheri MS, Nabavi SM. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2. Arch Med Sci. 2020; 16(3):519-521. PMID: 32399097.
      Citations: 7